This press release has been sponsored by IHT Medical.
IHT Medical is pleased to announce the start of enrolment in the CLARITE pivotal trial by René Chapot (Alfried Krupp Krankenhaus, Essen, Germany). This study focuses on the endovascular treatment of arteriovenous pathologies using the Obtura® liquid embolic system.
Obtura is a next-generation liquid embolic agent featuring a novel, first-in-class radiopacity-loss mechanism, requiring no shaking and offering superior penetration. These unique properties provide a new perspective on embolisation procedures.
The CLARITE trial aims to enrol 110 patients across six European centres in Spain and Germany. Its objective is to validate, through a prospective, multicentre clinical trial, the promising results obtained in the CLARIDAD trial—led by Juan Carlos Llibre-Guerra (Hospital Universitario de Salamanca, Salamanca, Spain)—on the curative embolisation of brain arteriovenous pathologies.
The inclusion of Alfried Krupp Krankenhaus expands the efforts initiated by Spanish centres led by Llibre-Guerra alongside Alberto Gil (Hospital Universitario Marqués de Valdecilla, Santander, Spain) and Leopoldo Guimaraens (Hospital Universitari General de Catalunya, Barcelona, Spain).
“Obtura is the most significant innovation in the neurointerventional field in the last 20 years,” said Chapot, head of Neuroradiology at Alfried Krupp Krankenhaus and principal investigator of the CLARITE trial.
The Radiology Department at Alfried Krupp Krankenhaus—led by Chapot—is recognised as one of the world’s most prestigious centres for the minimally invasive treatment of complex neurovascular diseases, driven by Chapot’s exceptional innovative spirit.
IHT Medical is a European medical device company founded in 1980 in Barcelona, Spain. IHT, a family-owned company, specialises in developing medical devices that deliver disruptive or significant value to the interventional field.
For more information, contact [email protected].
